Beyond Zolbetuximab: Next-Generation Targeting Strategies for CLDN18.2. (PubMed, J Gastrointest Cancer) - Sep 3, 2026 - "Tissue immunohistochemistry remains the reference method for treatment selection; circulating tumor DNA cannot currently reproduce membranous protein intensity or spatial distribution, and liquid-biopsy approaches for CLDN18.2 reassessment remain investigational."
Journal • Review • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Oncology • Solid Tumor • CLDN18
|
|
Hiroyuki Nagashima; Koshi Fujikawa; Tamotsu Sagawa
|